Welcome to our dedicated page for IGC Pharma SEC filings (Ticker: IGC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IGC’s Alzheimer’s candidate IGC-AD1 brings promising science—but it also means pages of dense trial data, patent claims, and risk factors tucked inside every SEC document. Finding when Phase 2 costs hit the balance sheet or spotting fresh FDA correspondence often feels impossible.
Stock Titan solves that problem. Our platform ingests each IGC quarterly earnings report 10-Q filing, IGC annual report 10-K simplified, and IGC 8-K material events explained the moment they post to EDGAR. AI-powered summaries translate pharmacology jargon and accounting footnotes into clear language, while real-time alerts surface IGC Form 4 insider transactions real-time so you never miss an executive stock move. Want the numbers fast? Click for IGC earnings report filing analysis that compares R&D spend to cash runway in seconds.
Go deeper into what matters for a clinical-stage biotech. Our coverage connects each filing type to key decisions: use the IGC proxy statement executive compensation to track performance milestones, scan IGC insider trading Form 4 transactions for confidence signals before data read-outs, and rely on AI to flag new risk language about cannabinoid regulation. From understanding IGC SEC documents with AI to monitoring IGC executive stock transactions Form 4, Stock Titan equips you to act on information first—without wading through hundreds of pages.
IGC Pharma (NYSE:IGC) filed its Form 10-K for the fiscal year ended March 31 2025. The company remains a non-accelerated, smaller reporting company with 83.9 million common shares outstanding and an aggregate non-affiliate market value of $29.7 million as of Sept 30 2024.
Management reiterates its mission to advance IGC-AD1—now in Phase 2 clinical trials for Alzheimer’s agitation—while investing in an AI-driven early-diagnosis platform. The filing lists extensive risk factors covering cash sufficiency, regulatory approvals, IP protection, clinical-trial funding, and cybersecurity. No restatements, auditor ICFR attestation, or material acquisitions/dispositions were disclosed. Standard sections (MD&A, financials, controls) are included, and the company confirms timely SEC compliance.
FAQ
What is the current stock price of IGC Pharma (IGC)?
What is the market cap of IGC Pharma (IGC)?
